NEW CIS-IMIDAZOLINES Russian patent published in 2011 - IPC C07D403/06 C07D401/14 C07D413/14 A61K31/496 A61K31/4523 A61K31/5377 

Abstract RU 2408593 C2

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds of formula I and its pharmaceutically acceptable salts. In formula (I) , R stands for 6-unit ring, containing one ore two heteroatoms of nitrogen, and substituted with group selected from the following groups: (lower)alkyl, -C(O)-R1, (lower)alkyl, substituted with group -SO2-(lower)alkyl, (lower)alkyl, substituted with group -C(O)-R1, -SO2-(lower)alkyl, or 5-unit saturated ring, containing one heteroatom of nitrogen, R1 is selected from group, including (lower)alkyl, -N((lower)alkyl)2, or R1 stands for 6-unit saturated ring, containing two heteroatoms, selected from N and O, X1 and X2 are independently selected from group, including hydrogen, (lower)alkoxy, each Y1 and Y2 are independently selected from group, including -Cl and -Br, and absolute stoichiometric configuration in position 4 and 5 imidazoline ring includes S and R configuration, accordingly. Invention also relates to pharmaceutical composition, having inhibiting activity regarding interaction of MDM2 - p-53, containing efficient amount of invention compound.

EFFECT: production of compounds, having inhibiting activity as regards interaction of MDM2-p-53.

12 cl, 17 ex

Similar patents RU2408593C2

Title Year Author Number
DERIVANTS OF 2, 4, 5-TRIPHENYLIMIDAZOLINE AS INACTIVATORS OF INTERACTION BETWEEN P53 AND MDM2 PROTEINS DESIGNED FOR APPLICATION AS ANTICANCER DRUGS 2006
  • Din Tsin'Tszi
  • Grejvs Brehdford Dzhejms
  • Kong Norman
  • Lju Tszin'Tszun'
  • Lovej Allen Dzhon
  • Pitstsolato Dzhakomo
  • Roberts Dzhon Loson
  • So Sunsau
  • Vu Binkh Tkhankh
  • Vovkulich Piter Majkl
RU2442779C2
CIS-2,4,5-TRIARYLIMIDAZOLINES AND USE THEREOF AS ANTICANCER MEDICINAL AGENTS 2006
  • Fotukhi Nader
  • Khejli Gregori Dzhej
  • Simonsen Klaus B.
  • Vu Binkh Tankh
  • Uehbber Stiven Ehvan
RU2411238C2
CIS-2,4,5-TRIPHENYLIMIDAZOLINES AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF 2002
  • Kong Norman
  • Lju Ehmili Ajtszun'
  • Vu Binkh Tkhankh
RU2305095C2
CIS-IMIDAZOLINES AS MDM2 INHIBITORS 2004
  • Fotui Nader
  • Lju Ehmili Ajtsun'
  • Vu Binkh Tkhankh
RU2354649C2
CHIRAL CIS-IMIDAZOLINES 2008
  • Bartkovich Dejvid Dzhozef
  • Kaj Tszjan'Pin
  • Chu Sin'Tszi
  • Li Khontszju
  • Lavi Allen Dzhon
  • Vu Binkh Tkhankh
  • Chzhao Chun'Lin'
RU2487127C2
NEW DISPIRO-INDOLINONES, MDM2/p53 INTERACTION INHIBITORS, METHOD FOR PRODUCTION AND APPLICATION 2015
  • Ivanenkov Yan Andreevich
  • Mazhuga Aleksandr Georgievich
  • Beloglazkina Elena Kimovna
  • Beloglazkina Anastasiya Aleksandrovna
  • Veselov Mark Sergeevich
  • Kukushkin Maksim Evgenevich
RU2629750C2
SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES 2009
  • Din Tsintszi
  • Tszjan Nan'
  • Lju Tszin'Tszun'
  • Ross Tina Morgan
  • Chzhan Tszin
  • Chzhan Chzhumin
RU2506257C2
DISPIROINDOLINONES BASED ON RHODANINES AS P53-MDM2 INHIBITORS OF PROTEIN-PROTEIN INTERACTION 2019
  • Beloglazkina Anastasiya Aleksandrovna
  • Mazhuga Aleksandr Georgievich
  • Beloglazkina Elena Kimovna
  • Mefedova Sofiya Romanovna
  • Karpov Nikita Aleksandrovich
RU2730286C1
METHOD OF OBTAINING DISPIROINDOLINONES 2018
  • Mazhuga Aleksandr Georgievich
  • Beloglazkina Elena Kimovna
  • Ivanenkov Yan Andreevich
  • Beloglazkina Anastasiya Aleksandrovna
  • Kukushkin Maksim Evgenevich
  • Barashkin Aleksandr Anatolevich
RU2682678C1
NK1/NK3 DOUBLE AGONISTS FOR TREATING SCHIZOPHRENIA 2004
  • Khoffman Torsten
  • Koblet Andreas
  • Peters Jens-Uve
  • Shnider Patrik
  • Slejt Ehndr'Ju
  • Shtadler Khajnts
RU2347777C2

RU 2 408 593 C2

Authors

Khejli Gregori Dzhej

Kong Norman

Lju Ehmili Ajtsun'

Vu Binkh Tkhankh

Dates

2011-01-10Published

2005-06-08Filed